Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH) -- Ignore unavailable to you. Want to Upgrade?

To: Biojunkie who wrote (56)	4/1/1998 6:11:00 PM
From: BDR	Read Replies (1) \| Respond to of 138

<<A Poster by this doctor was presented at the world aids conference in 1996. >> Thanks for the info. Where has this been published so that anyone else can read it and evaluate it? Where is Dr.Salvato located and do you have a phone number for him? What is meant by an "analog of DHEA"? If it is not DHEA, what is it? The company's own filings with the SEC describe Inactivin as a special formulation of DHEA but do not indicate that it is anything but DHEA.

To: Biojunkie who wrote (56)	4/1/1998 10:40:00 PM
From: Alan Lee	Respond to of 138

<< The people on this thread continue to confuse people regarding the company,s lead product candidate as DHEA. >> Well, you've certainly managed to confuse me ... first you say that Inactivin is not DHEA (contrary to the SEC filings, as Dale pointed out), then you cite a clinical trail on DHEA, apparently as evidence that Inactivin is useful for HIV therapy. So if Inactivin is not DHEA, how is this relevant? How about some links to support some of this?